NLRP3 and myocardial infarction: Consistent with this finding, the authors found that pharmacological inhibition of the NLRP3 inflammasome (using 16673-34-0, an intermediate of glyburide substrate free of the cyclohexylurea moiety, involved in insulin release), reduced MI size after 24 h reperfusion, when it was administered at the onset of reperfusion or 1 h after reperfusion (but not after 3 h of reperfusion) (Toldo et al., 2016), making it possible to intervene after reperfusion has already taken place in AMI patients treated by PPCI.